JPH10503935A - 核レセプターファミリーに属するオーファンレセプター上のor−1 - Google Patents
核レセプターファミリーに属するオーファンレセプター上のor−1Info
- Publication number
- JPH10503935A JPH10503935A JP8507031A JP50703196A JPH10503935A JP H10503935 A JPH10503935 A JP H10503935A JP 8507031 A JP8507031 A JP 8507031A JP 50703196 A JP50703196 A JP 50703196A JP H10503935 A JPH10503935 A JP H10503935A
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- receptor
- acid sequence
- sequence
- rxr
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000006255 nuclear receptors Human genes 0.000 title claims abstract description 25
- 108020004017 nuclear receptors Proteins 0.000 title claims abstract description 25
- 108020005497 Nuclear hormone receptor Proteins 0.000 title claims abstract description 22
- 102000016978 Orphan receptors Human genes 0.000 title description 4
- 108070000031 Orphan receptors Proteins 0.000 title description 4
- 102000005962 receptors Human genes 0.000 claims abstract description 17
- 108020003175 receptors Proteins 0.000 claims abstract description 17
- 108091028043 Nucleic acid sequence Proteins 0.000 claims abstract description 16
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract 12
- 238000000338 in vitro Methods 0.000 claims description 7
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 claims description 3
- 239000003446 ligand Substances 0.000 claims description 3
- 229930002330 retinoic acid Natural products 0.000 claims description 3
- 230000011664 signaling Effects 0.000 claims description 3
- 229960001727 tretinoin Drugs 0.000 claims description 3
- 150000001875 compounds Chemical class 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 238000005734 heterodimerization reaction Methods 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 101150095442 Nr1h2 gene Proteins 0.000 description 70
- 108010038912 Retinoid X Receptors Proteins 0.000 description 23
- 102000034527 Retinoid X Receptors Human genes 0.000 description 23
- 210000004027 cell Anatomy 0.000 description 23
- 230000014509 gene expression Effects 0.000 description 17
- 108020004999 messenger RNA Proteins 0.000 description 15
- 150000001413 amino acids Chemical class 0.000 description 14
- SHGAZHPCJJPHSC-ZVCIMWCZSA-N 9-cis-retinoic acid Chemical compound OC(=O)/C=C(\C)/C=C/C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-ZVCIMWCZSA-N 0.000 description 11
- 229960001445 alitretinoin Drugs 0.000 description 11
- 210000001519 tissue Anatomy 0.000 description 11
- 108090000623 proteins and genes Proteins 0.000 description 10
- 230000004568 DNA-binding Effects 0.000 description 8
- 235000001014 amino acid Nutrition 0.000 description 7
- 235000018102 proteins Nutrition 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 241000700159 Rattus Species 0.000 description 6
- 210000004185 liver Anatomy 0.000 description 6
- 108020004414 DNA Proteins 0.000 description 5
- 238000009826 distribution Methods 0.000 description 5
- 210000000981 epithelium Anatomy 0.000 description 5
- 238000002372 labelling Methods 0.000 description 5
- 108091034117 Oligonucleotide Proteins 0.000 description 4
- 108091027981 Response element Proteins 0.000 description 4
- 238000010367 cloning Methods 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 230000001605 fetal effect Effects 0.000 description 4
- 230000001817 pituitary effect Effects 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- 102100024321 Alkaline phosphatase, placental type Human genes 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 101001093899 Homo sapiens Retinoic acid receptor RXR-alpha Proteins 0.000 description 3
- 102100038476 Oxysterols receptor LXR-alpha Human genes 0.000 description 3
- 101710111784 Oxysterols receptor LXR-alpha Proteins 0.000 description 3
- 102100035178 Retinoic acid receptor RXR-alpha Human genes 0.000 description 3
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 3
- 210000001638 cerebellum Anatomy 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 210000002216 heart Anatomy 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 210000002569 neuron Anatomy 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 108010031345 placental alkaline phosphatase Proteins 0.000 description 3
- 239000013612 plasmid Substances 0.000 description 3
- 230000004043 responsiveness Effects 0.000 description 3
- 210000003079 salivary gland Anatomy 0.000 description 3
- 210000001550 testis Anatomy 0.000 description 3
- 210000001541 thymus gland Anatomy 0.000 description 3
- 210000001685 thyroid gland Anatomy 0.000 description 3
- 229940036555 thyroid hormone Drugs 0.000 description 3
- 239000005495 thyroid hormone Substances 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- 239000011701 zinc Substances 0.000 description 3
- 229910052725 zinc Inorganic materials 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 108700024394 Exon Proteins 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- AUYYCJSJGJYCDS-LBPRGKRZSA-N Thyrolar Chemical class IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-LBPRGKRZSA-N 0.000 description 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 210000001943 adrenal medulla Anatomy 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 239000012894 fetal calf serum Substances 0.000 description 2
- 210000001320 hippocampus Anatomy 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 238000007901 in situ hybridization Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 210000001165 lymph node Anatomy 0.000 description 2
- 210000000653 nervous system Anatomy 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 210000001672 ovary Anatomy 0.000 description 2
- 210000002990 parathyroid gland Anatomy 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 210000002307 prostate Anatomy 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 210000001525 retina Anatomy 0.000 description 2
- 102000003702 retinoic acid receptors Human genes 0.000 description 2
- 108090000064 retinoic acid receptors Proteins 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 210000002027 skeletal muscle Anatomy 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 230000002889 sympathetic effect Effects 0.000 description 2
- 102000004217 thyroid hormone receptors Human genes 0.000 description 2
- 108090000721 thyroid hormone receptors Proteins 0.000 description 2
- 102000009310 vitamin D receptors Human genes 0.000 description 2
- 108050000156 vitamin D receptors Proteins 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- XZKIHKMTEMTJQX-UHFFFAOYSA-N 4-Nitrophenyl Phosphate Chemical compound OP(O)(=O)OC1=CC=C([N+]([O-])=O)C=C1 XZKIHKMTEMTJQX-UHFFFAOYSA-N 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 108091062157 Cis-regulatory element Proteins 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 108010054576 Deoxyribonuclease EcoRI Proteins 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 201000009051 Embryonal Carcinoma Diseases 0.000 description 1
- 208000003098 Ganglion Cysts Diseases 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 101000640876 Homo sapiens Retinoic acid receptor RXR-beta Proteins 0.000 description 1
- 101000640882 Homo sapiens Retinoic acid receptor RXR-gamma Proteins 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 108091081548 Palindromic sequence Proteins 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 101100187468 Rattus norvegicus Nr1h2 gene Proteins 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- 102100034253 Retinoic acid receptor RXR-beta Human genes 0.000 description 1
- 102100034262 Retinoic acid receptor RXR-gamma Human genes 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 208000005400 Synovial Cyst Diseases 0.000 description 1
- 230000033540 T cell apoptotic process Effects 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- VXFJYXUZANRPDJ-WTNASJBWSA-N Trandopril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](C[C@H]2CCCC[C@@H]21)C(O)=O)CC1=CC=CC=C1 VXFJYXUZANRPDJ-WTNASJBWSA-N 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 241000607479 Yersinia pestis Species 0.000 description 1
- HMNZFMSWFCAGGW-XPWSMXQVSA-N [3-[hydroxy(2-hydroxyethoxy)phosphoryl]oxy-2-[(e)-octadec-9-enoyl]oxypropyl] (e)-octadec-9-enoate Chemical compound CCCCCCCC\C=C\CCCCCCCC(=O)OCC(COP(O)(=O)OCCO)OC(=O)CCCCCCC\C=C\CCCCCCCC HMNZFMSWFCAGGW-XPWSMXQVSA-N 0.000 description 1
- 210000003486 adipose tissue brown Anatomy 0.000 description 1
- 210000000593 adipose tissue white Anatomy 0.000 description 1
- 210000004404 adrenal cortex Anatomy 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N aspartic acid group Chemical group N[C@@H](CC(=O)O)C(=O)O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000027455 binding Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 235000011089 carbon dioxide Nutrition 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000011712 cell development Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 210000004720 cerebrum Anatomy 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 210000003737 chromaffin cell Anatomy 0.000 description 1
- 230000004186 co-expression Effects 0.000 description 1
- 238000012761 co-transfection Methods 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 125000000151 cysteine group Chemical class N[C@@H](CS)C(=O)* 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 210000003372 endocrine gland Anatomy 0.000 description 1
- 210000000750 endocrine system Anatomy 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 210000000918 epididymis Anatomy 0.000 description 1
- 201000010063 epididymitis Diseases 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 210000001752 female genitalia Anatomy 0.000 description 1
- 210000004996 female reproductive system Anatomy 0.000 description 1
- MKXKFYHWDHIYRV-UHFFFAOYSA-N flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 239000000833 heterodimer Substances 0.000 description 1
- 239000000710 homodimer Substances 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 108091008039 hormone receptors Proteins 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 210000000244 kidney pelvis Anatomy 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 210000002332 leydig cell Anatomy 0.000 description 1
- 108020001756 ligand binding domains Proteins 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 210000000260 male genitalia Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 210000000754 myometrium Anatomy 0.000 description 1
- 210000004248 oligodendroglia Anatomy 0.000 description 1
- 239000002751 oligonucleotide probe Substances 0.000 description 1
- 210000000287 oocyte Anatomy 0.000 description 1
- 210000001328 optic nerve Anatomy 0.000 description 1
- 230000000849 parathyroid Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 210000000578 peripheral nerve Anatomy 0.000 description 1
- 210000004560 pineal gland Anatomy 0.000 description 1
- 210000003635 pituitary gland Anatomy 0.000 description 1
- 238000013492 plasmid preparation Methods 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 235000013930 proline Nutrition 0.000 description 1
- 210000004994 reproductive system Anatomy 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 210000001995 reticulocyte Anatomy 0.000 description 1
- 210000001581 salivary duct Anatomy 0.000 description 1
- 210000004116 schwann cell Anatomy 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 210000001625 seminal vesicle Anatomy 0.000 description 1
- 210000001741 seminiferous epithelium Anatomy 0.000 description 1
- 210000000413 sensory ganglia Anatomy 0.000 description 1
- 235000004400 serine Nutrition 0.000 description 1
- 210000000717 sertoli cell Anatomy 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 210000001057 smooth muscle myoblast Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 210000003594 spinal ganglia Anatomy 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000003270 steroid hormone Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 210000002222 superior cervical ganglion Anatomy 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 210000000331 sympathetic ganglia Anatomy 0.000 description 1
- 235000008521 threonine Nutrition 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 210000005239 tubule Anatomy 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 210000003741 urothelium Anatomy 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 210000001177 vas deferen Anatomy 0.000 description 1
- 201000010653 vesiculitis Diseases 0.000 description 1
- 230000009278 visceral effect Effects 0.000 description 1
- 235000005282 vitamin D3 Nutrition 0.000 description 1
- 239000011647 vitamin D3 Substances 0.000 description 1
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 1
- 229940021056 vitamin d3 Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70567—Nuclear receptors, e.g. retinoic acid receptor [RAR], RXR, nuclear orphan receptors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Toxicology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Biomedical Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Wood Science & Technology (AREA)
- High Energy & Nuclear Physics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Compounds Of Unknown Constitution (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1. 図1のアミノ酸配列または図1に示されるアミノ酸配列と実質的に同じア ミノ酸配列またはその配列に機能的に類似のアミノ酸配列を有する、単離された 核レセプター。 2. ラット由来の請求項1に記載のレセプター。 3. DNA配列-AGGTCA-の繰返しを少なくとも1個含むDNA配列に結合する請求項 1または2に記載のレセプター。 4. DNA配列がAGTCAGGTCACTCGAGGTCAGTCAを含む請求項3に記載のレセプター 。 5. RXRとヘテロ二量体化して複合体を形成する請求項1〜4のいずれか1つ に記載のレセプター。 6. 前記請求項のいずれかに記載のレセプターおよびRXRを含む複合体。 7. 図1のアミノ酸配列に少なくとも90%同一である請求項1に記載のレセプ ターをコードするアミノ酸配列。 8. 図1のアミノ酸配列に少なくとも95%同一である請求項1に記載のレセプ ターをコードするアミノ酸配列。 9. 請求項1〜5のいずれか1つに記載の核レセプターまたは機能的に類似の 核レセプターをコードするDNA配列。 10. DNA配列が図2に示されるものであるか又はその 配列に実質的に類似のDNA配列である請求項9に記載のDNA配列。 11. 請求項1〜5のいずれか1つに記載の核レセプター又は請求項6に記載 の複合体又はそのリガンドの医薬中での使用。 12. インビトロ又はインビボでのレチノイン酸シグナリングを調整する請求 項1〜5のいずれか1つに記載の核レセプターの使用。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9416536.2 | 1994-08-16 | ||
GB9416536A GB9416536D0 (en) | 1994-08-16 | 1994-08-16 | Orphan receptor |
PCT/EP1995/003247 WO1996005300A2 (en) | 1994-08-16 | 1995-08-16 | Or-1 on orphan receptor belonging to the nuclear receptor family |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH10503935A true JPH10503935A (ja) | 1998-04-14 |
JP3533499B2 JP3533499B2 (ja) | 2004-05-31 |
Family
ID=10759929
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP50703196A Expired - Fee Related JP3533499B2 (ja) | 1994-08-16 | 1995-08-16 | 核レセプターファミリーに属するオーファンレセプター上のor−1 |
Country Status (13)
Country | Link |
---|---|
US (4) | US6277976B1 (ja) |
EP (1) | EP0773999B1 (ja) |
JP (1) | JP3533499B2 (ja) |
KR (1) | KR100407285B1 (ja) |
AT (1) | ATE215123T1 (ja) |
AU (1) | AU701922B2 (ja) |
CA (1) | CA2197651C (ja) |
DE (2) | DE773999T1 (ja) |
DK (1) | DK0773999T3 (ja) |
ES (1) | ES2171549T3 (ja) |
GB (1) | GB9416536D0 (ja) |
PT (1) | PT773999E (ja) |
WO (1) | WO1996005300A2 (ja) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5932699A (en) * | 1995-01-13 | 1999-08-03 | The General Hospital Corporation | Retinoid X receptor-interacting polypeptides |
MXPA03007492A (es) | 2001-02-20 | 2004-10-15 | Rheogene Holdings Inc | Receptores de retinoide x quimerico y su uso en un sistema de expresion de gen inducible basado en receptor de ecdisona novedoso. |
EP2275558B1 (en) | 2001-02-20 | 2018-11-28 | Intrexon Corporation | Novel substitution mutant receptors and their use in a nuclear receptor-based inducible gene expression system |
US6924311B2 (en) | 2001-10-17 | 2005-08-02 | X-Ceptor Therapeutics, Inc. | Methods for affecting various diseases utilizing LXR compounds |
CA2517027A1 (en) | 2002-02-25 | 2003-09-04 | Vaxiion Therapeutics, Inc. | Minicell compositions and methods |
US20030228607A1 (en) * | 2002-04-15 | 2003-12-11 | Wagner Brandee Lynn | Screening method and modulators having an improved therapeutic profile |
US20040096089A1 (en) * | 2002-08-16 | 2004-05-20 | David Borsook | Non-invasive functional imaging of peripheral nervous system activation in humans and animals |
US8377027B2 (en) * | 2005-04-29 | 2013-02-19 | Kimberly-Clark Worldwide, Inc. | Waist elastic members for use in absorbent articles |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2115452A1 (en) * | 1991-09-17 | 1993-04-01 | Ronald M. Evans | Receptor of the thyroid/steroid hormone receptor superfamily |
WO1995013373A1 (en) * | 1993-11-10 | 1995-05-18 | Arch Development Corporation | Ubiquitous nuclear receptor: compositions and methods |
-
1994
- 1994-08-16 GB GB9416536A patent/GB9416536D0/en active Pending
-
1995
- 1995-08-16 AU AU33844/95A patent/AU701922B2/en not_active Ceased
- 1995-08-16 DE DE0773999T patent/DE773999T1/de active Pending
- 1995-08-16 KR KR1019970700974A patent/KR100407285B1/ko not_active IP Right Cessation
- 1995-08-16 DE DE69526087T patent/DE69526087T2/de not_active Expired - Lifetime
- 1995-08-16 PT PT95930467T patent/PT773999E/pt unknown
- 1995-08-16 EP EP95930467A patent/EP0773999B1/en not_active Expired - Lifetime
- 1995-08-16 WO PCT/EP1995/003247 patent/WO1996005300A2/en not_active Application Discontinuation
- 1995-08-16 ES ES95930467T patent/ES2171549T3/es not_active Expired - Lifetime
- 1995-08-16 JP JP50703196A patent/JP3533499B2/ja not_active Expired - Fee Related
- 1995-08-16 CA CA002197651A patent/CA2197651C/en not_active Expired - Fee Related
- 1995-08-16 US US08/776,844 patent/US6277976B1/en not_active Expired - Fee Related
- 1995-08-16 AT AT95930467T patent/ATE215123T1/de not_active IP Right Cessation
- 1995-08-16 DK DK95930467T patent/DK0773999T3/da active
-
2001
- 2001-07-19 US US09/909,326 patent/US6617120B2/en not_active Expired - Fee Related
- 2001-07-19 US US09/909,446 patent/US20020052489A1/en not_active Abandoned
- 2001-07-19 US US09/909,325 patent/US6525188B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
WO1996005300A2 (en) | 1996-02-22 |
JP3533499B2 (ja) | 2004-05-31 |
US6277976B1 (en) | 2001-08-21 |
KR970704881A (ko) | 1997-09-06 |
AU701922B2 (en) | 1999-02-11 |
DE773999T1 (de) | 2001-07-19 |
DE69526087D1 (de) | 2002-05-02 |
WO1996005300A3 (en) | 1996-05-30 |
DE69526087T2 (de) | 2002-09-12 |
US6525188B2 (en) | 2003-02-25 |
US20020128461A1 (en) | 2002-09-12 |
GB9416536D0 (en) | 1994-10-12 |
ATE215123T1 (de) | 2002-04-15 |
CA2197651A1 (en) | 1996-02-22 |
EP0773999A2 (en) | 1997-05-21 |
US20020052489A1 (en) | 2002-05-02 |
KR100407285B1 (ko) | 2004-04-29 |
US20020115847A1 (en) | 2002-08-22 |
EP0773999B1 (en) | 2002-03-27 |
AU3384495A (en) | 1996-03-07 |
ES2171549T3 (es) | 2002-09-16 |
DK0773999T3 (da) | 2002-07-22 |
US6617120B2 (en) | 2003-09-09 |
PT773999E (pt) | 2002-08-30 |
CA2197651C (en) | 2005-06-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Varghese et al. | Comparative analysis of mammalian stanniocalcin genes | |
Compagnone et al. | Novel role for the nuclear phosphoprotein SET in transcriptional activation of P450c17 and initiation of neurosteroidogenesis | |
JP3131649B2 (ja) | オーファン レセプター | |
Shigeta et al. | The mouse estrogen receptor-related orphan receptor alpha 1: molecular cloning and estrogen responsiveness | |
Orwig et al. | Decidual/trophoblast prolactin-related protein: characterization of gene structure and cell-specific expression | |
Binder et al. | Steroid receptors in the uterus and ovary | |
Bandoh et al. | Differential expression of NGFI‐B and RNR‐1 genes in various tissues and developing brain of the rat: comparative study by quantitative reverse transcription‐polymerase chain reaction | |
JPH10503935A (ja) | 核レセプターファミリーに属するオーファンレセプター上のor−1 | |
JPH11502402A (ja) | レチノイドx受容体相互作用性ポリペプチドならびに関連する分子および方法 | |
Macrae et al. | Cloning, characterization, and chromosomal localization of rec1. 3, a member of the G-protein-coupled receptor family highly expressed in brain | |
Jehan et al. | The mouse vitamin D receptor is mainly expressed through an Sp1-driven promoter in vivo | |
US20070020266A1 (en) | Gpr54 receptor agonist and antagonist useful for the treatment of gonadotropin related diseases | |
Hermann et al. | Regulatory functions of a non-ligand-binding thyroid hormone receptor isoform. | |
Ungefroren et al. | Biglycan gene expression in the human leiomyosarcoma cell line SK-UT-1: basal and protein kinase A-induced transcription involves binding of Sp1-like/Sp3 proteins in the proximal promoter region | |
Stansberg et al. | Cloning of the Atlantic salmon (Salmo salar) IL-1 receptor associated protein | |
Corthésy et al. | A liver protein fraction regulating hormone-dependent in vitro transcription from the vitellogenin genes induces their expression in Xenopus oocytes | |
Matsukawa et al. | Expression of prolactin receptor mRNA in the abdominal gland of the newt Cynops ensicauda | |
JP2001518293A (ja) | ヒトビタミンdレセプターのアイソフォーム | |
Linares et al. | C2PA, a new protein expressed during mouse spermatogenesis | |
Tiong et al. | A liver specific gene that is expressed in growth hormone transgenic mice and in normal female mice as a function of age | |
Rodrı́guez-Manzaneque et al. | Control by thyroid hormone of NGFI-A gene expression in lung: regulation of NGFI-A promoter activity | |
Wei | New models and insights in steroid hormone action | |
Davies et al. | Expression of GLUT2 in insulin-secreting AtT20 pituitary cells | |
Zupo et al. | Evidences that Progesterone Receptor B decreases Estrogen Receptor α gene expression through its interaction to a half-PRE site at Estrogen Receptor alfa gene promoter. | |
Sharma | Guanylate Cyclase |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20040122 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20040204 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20040224 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20080319 Year of fee payment: 4 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090319 Year of fee payment: 5 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100319 Year of fee payment: 6 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100319 Year of fee payment: 6 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110319 Year of fee payment: 7 |
|
LAPS | Cancellation because of no payment of annual fees |